Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Zydus-Lifesciences-Ltd"

26 News Found

Briefs: Caplin Steriles, Zydus  and APL Healthcare
Drug Approval | September 20, 2023

Briefs: Caplin Steriles, Zydus and APL Healthcare

Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients


Briefs: Link Pharma Chem and Zydus
News | July 11, 2023

Briefs: Link Pharma Chem and Zydus

USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad


Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities
Diagnostic Center | June 10, 2023

Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities

The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52


Zydus granted Orphan Drug Designation by USFDA for ZYIL1
Drug Approval | March 22, 2023

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates


Zydus enters into BTA for purchase from Watson Pharma
News | November 30, 2022

Zydus enters into BTA for purchase from Watson Pharma

The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.


Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Healthcare | November 18, 2022

Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast

Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning


Zydus receives EIR with VAI from USFDA for Moraiya facility
Drug Approval | November 08, 2022

Zydus receives EIR with VAI from USFDA for Moraiya facility

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)


Zydus Announces New Data Presentations at The Liver Meeting 2022
News | November 04, 2022

Zydus Announces New Data Presentations at The Liver Meeting 2022

Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis


BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
Drug Approval | September 22, 2022

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.


Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal
News | September 10, 2022

Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal

MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions